Products for Research Use Only
RegisterLogin

OLHHA

CAT: 0804-HY-139230-01Size: 100 µgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-139230-01Size:100 µg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
OLHHA is a dual CB1 receptor antagonist and PPARα agonist. OLHHA also is a alcohol intake inhibitor with an EC50 value of 0.2 mg/kg. OLHHA reduces both hepatic lipid accumulation and circulating triglyceride levels. OLHHA shows anti-steatotic activity and has the potential for the research of non-alcoholic fatty liver disease (NAFLD) [1][2].
CAS Number
1258011-97-0
UNSPSC
12352005
Hazard Statement
H225-H319
Target
Cannabinoid Receptor; PPAR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling; Vitamin D Related/Nuclear Receptor
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/olhha.html
Solubility
10 mM in DMSO
Smiles
CCCCCCCC/C=C\CCCCCCCC(NC(C)CC1=CC=C(O)C(O)=C1)=O
Molecular Formula
C27H45NO3
Molecular Weight
431.65
Precautions
P210-P233-P240-P241-P242-P243-P264-P280-P303+P361+P353-P305+P351+P338-P370+P378-P403+P235-P501
References & Citations
[1]Alen F, et al. PPARα/CB1 receptor dual ligands as a novel therapy for alcohol use disorder: Evaluation of a novel oleic acid conjugate in preclinical rat models. Biochem Pharmacol. 2018 Nov;157:235-243.|[2]Decara JM, et al. Treatment with a novel oleic-acid-dihydroxyamphetamine conjugation ameliorates non-alcoholic fatty liver disease in obese Zucker rats. Dis Model Mech. 2015 Oct 1;8 (10) :1213-25.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Alternative Products

CatalogName
BA5205-.1OLHHA

Popular Products